adults who currently take GLP-1 medications for weight loss purposes has risen to 11% in 2026, up significantly from 3% in 2024
Medication Sourcing Strategy: Following the landmark March 2026 partnership between Hims and Novo Nordisk, Hims has pivoted toward providing FDA-approved Wegovy and Ozempic as its primary offering
This method of administration, while perhaps daunting to some, has been well-received due to its effectiveness and the convenience of once-weekly dosing
The pancreatic carcinoma cell line PANC-1, prostate adenocarcinoma cell line PC-3, breast cancer cell line (MCF7 and 4T1), and lung adenocarcinoma cell line NCI-H1975 were purchased from American Type Culture Collection (USA)
Research continues to reveal the lymphatic systems importance, and liposomal technology could transform how we supplement essential nutrients